|Bid||10.59 x 1000|
|Ask||10.65 x 900|
|Day's Range||10.59 - 10.60|
|52 Week Range||9.84 - 12.00|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
BALA CYNWYD, PA / ACCESSWIRE / May 3, 2021 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Montes Archimedes Acquisition Corp. ("Montes Archimedes " or the "Company") (NASDAQ:MAAC) for possible breaches of fiduciary duty and other violations of federal and state law in connection with a merger agreement pursuant to which Montes Archimedes, a special purpose acquisition company, will combine with Roivant Sciences, a biopharmaceutical and healthcare technology company, and result in Roivant Sciences becoming a publicly-listed company.
Roivant Sciences, a biopharmaceutical and healthcare technology company, and Montes Archimedes Acquisition Corp. (Nasdaq: MAAC), a special purpose acquisition company sponsored by Patient Square Capital, today announced that they have entered into a definitive business combination agreement. Upon closing of the transaction, outstanding shares and warrants of MAAC will be exchanged for newly issued shares and warrants of Roivant Sciences, which is expected to be listed on Nasdaq under the new ticker symbol "ROIV."
Every investor in Montes Archimedes Acquisition Corp. ( NASDAQ:MAAC ) should be aware of the most powerful shareholder...